Document is current
Any future updates will be listed below
-
Authors
Dibus, Nikol
Salyova, Eva https://orcid.org/0000-0001-7947-5778
Kolarova, Karolina
Abdirov, Alikhan https://orcid.org/0009-0002-8233-6968
Pagano, Michele https://orcid.org/0000-0003-3210-2442
Stepanek, Ondrej https://orcid.org/0000-0002-2735-3311
Cermak, Lukas https://orcid.org/0000-0002-8777-3692
-
Funding
Funding for this research was provided by:
Agentura Pro Zdravotnický Výzkum České Republiky (NU21-08-00312)
EU Next generation E (LX22NPO5103)
Czech Science Foundation (GA22-18046S)
Czech Science Foundation (GA24-10435S)
The Charles University Grant Agency (393722)
SVV (260637)
- License Information
-
More Information
Article History
Received: 7 September 2023
Revised: 5 March 2024
Accepted: 13 June 2024
First Online: 12 September 2024
Disclosure and competing interests statement
: MP is a scientific cofounder of SEED Therapeutics; receives research funding from and is a shareholder in Kymera Therapeutics; and is a consultant for, a member of the scientific advisory board of, and has financial interests in CullGen, SEED Therapeutics, Triana Biomedicines, and Umbra Therapeutics; however, no research funds were received from these entities, and the findings presented in this manuscript were not discussed with any person in these companies. The remaining authors declare no competing interests.
